Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3697798 | 0.87 | TDP1 (0.45) | TDP1CASP3LMNAALDH1A1GAA | |
| SCHEMBL6659850 | 0.83 | TDP1 (0.49) | TDP1CASP3LMNAALDH1A1GAA | |
| SCHEMBL6364898 | 0.83 | TDP1 (0.52) | TDP1CASP3LMNAALDH1A1GAA | |
| SCHEMBL11290023 | 0.81 | NPC1 (0.51) | TDP1CASP3LMNAALDH1A1KDM4E | |
| SCHEMBL19615470 | 0.81 | TDP1 (0.50) | TDP1CASP3LMNAALDH1A1GAA | |
| SCHEMBL6127956 | 0.81 | TDP1 (0.65) | TDP1CASP3LMNAALDH1A1GAA | |
| SCHEMBL6666103 | 0.81 | TDP1 (0.50) | TDP1CASP3LMNAALDH1A1GAA | |
| SCHEMBL29459229 | 0.81 | TDP1 (0.65) | TDP1CASP3LMNAALDH1A1GAA | |
| SCHEMBL14570441 | 0.81 | TDP1 (0.65) | TDP1CASP3LMNAALDH1A1GAA | |
| SCHEMBL4072630 | 0.79 | TDP1 (0.49) | TDP1CASP3LMNAALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007127930-A2 | COMPOUNDS AFFECTING GAP JUNCTION ACTIVITY | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20040176612-A1 | Method for preparing n-($g(v)-bromoalkyl)phthalimides | GILLET JEAN-PHILIPPE (FR) | 2004-09-09 | — | — | US | disclosed |
| US-20040176613-A1 | Method for preparing n-($g(v)-bromoalkyl)phthalimides | GILLET JEAN-PHILIPPE (FR) | 2004-09-09 | — | — | US | disclosed |
| EP-1436260-A1 | METHOD FOR PREPARING N-(V)-BROMOALKYL)PHTHALIMIDES | Albemarle Chemicals SAS (US) | 2004-07-14 | — | — | EP | disclosed |
| EP-1436261-A1 | METHOD FOR PREPARING N-($G(V)-BROMOALKYL)PHTHALIMIDES | Albemarle Chemicals SAS (US) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003027071-A1 | METHOD FOR PREPARING N-($G(V)-BROMOALKYL)PHTHALIMIDES | ALBEMARLE CHEMICALS SAS (US) | 2003-04-03 | — | — | WO | disclosed |
| WO-2003027070-A1 | METHOD FOR PREPARING N-($G(V)-BROMOALKYL)PHTHALIMIDES | ALBEMARLE CHEMICALS SAS (US) | 2003-04-03 | — | — | WO | disclosed |
| US-RE35631-E | Method of production of essentially pure melatonin and the method of solubilizing melatonin in water | IFLO S.A.S. (IT) | 1997-10-14 | — | — | US | disclosed |
| EP-0330625-B1 | Total synthesis method for making an indole structure derivative product class, of the triptamine type, in particular, melatonin or N-acetyl-5-methoxytriptamine type, having a high purity degree and easily soluble, for therapeutic use against acquired immuno-deficiency syndromes | I F L O S A S DI GIORGIO E ALD (IT) | 1995-12-20 | — | — | EP | disclosed |
| US-5122535-A | Mixing with adenosine; treating AIDS | IFLO S.A.S. (IT) | 1992-06-16 | — | — | US | disclosed |
| EP-0330625-A2 | Total synthesis method for making an indole structure derivative product class, of the triptamine type, in particular, melatonin or N-acetyl-5-methoxytriptamine type, having a high purity degree and easily soluble, for therapeutic use against acquired immuno-deficiency syndromes | I.F.L.O. S.a.s. di Giorgio e Aldo Laguzzi (IT) | 1989-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176612-A1 | Method for preparing n-($g(v)-bromoalkyl)phthalimides | GK, DGKA, GNG2 | TDP1 3482/4885CASP3 2150/4885LMNA 536/4885 |
| US-20040176613-A1 | Method for preparing n-($g(v)-bromoalkyl)phthalimides | GK, DGKG, DGKA | TDP1 3495/4885CASP3 1326/4885LMNA 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.